MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

DGX · NYSE

Quest Diagnostics Incorporated

Health Care · Medical Specialities

Reference price$231.61As of Jul 30, 2026
Market capitalization$25.56B
52-week range$166.75–$240.13
S&P 500 portfolio weight0.04%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$232.00+0.2% vs. reference
Average$252.70+9.1% vs. reference
High$265.00+14.4% vs. reference
7 Buy4 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$2.848 estimates
Expected range$2.79–$2.90Low to high EPS
Dec 2026$11.15Street EPS consensus
Dec 2027$11.95Street EPS consensus
Dec 2028$13.02Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+11.8% YoY$11.04B$9.87B
Operating income$1.56B$1.35B
Net income$0.99B$0.87B
Operating cash flow$1.89B$1.33B
Capital expenditures($0.53B)($0.43B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs

The Motley Fool

Why Quest Diagnostics Stock Climbed This Past Week

Zacks

Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) is a Great Choice

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.